Podcast
Questions and Answers
What distinguishes a Transient Ischemic Attack (TIA) from a full-blown ischemic stroke?
What distinguishes a Transient Ischemic Attack (TIA) from a full-blown ischemic stroke?
- TIA is characterized by permanent tissue damage.
- TIA involves bleeding into the CNS.
- TIA presents long-term neurologic deficits.
- TIA occurs without evidence of infarct. (correct)
Which risk factor is considered non-modifiable for stroke?
Which risk factor is considered non-modifiable for stroke?
- Age (correct)
- Diabetes
- Cigarette smoking
- Hypertension
What is the primary cause of a hemorrhagic stroke?
What is the primary cause of a hemorrhagic stroke?
- Reduced blood flow to brain tissue.
- Bleeding into the brain or CNS. (correct)
- Clot formation in the arteries.
- Plaque buildup in blood vessels.
Which statement about ischemic stroke is correct?
Which statement about ischemic stroke is correct?
What percentage of strokes has a history of a prior TIA?
What percentage of strokes has a history of a prior TIA?
Which of the following is considered a modifiable risk factor for stroke?
Which of the following is considered a modifiable risk factor for stroke?
What is the term for the ischemic tissue surrounding an infarction that can be salvaged?
What is the term for the ischemic tissue surrounding an infarction that can be salvaged?
Which condition is NOT typically associated with increased stroke risk?
Which condition is NOT typically associated with increased stroke risk?
Which of the following is a known risk factor for subarachnoid hemorrhage?
Which of the following is a known risk factor for subarachnoid hemorrhage?
What is a typical clinical presentation of subarachnoid hemorrhage?
What is a typical clinical presentation of subarachnoid hemorrhage?
In the management of anticoagulant-related hemorrhage, which treatment is used for patients on warfarin?
In the management of anticoagulant-related hemorrhage, which treatment is used for patients on warfarin?
Which of the following is a management strategy for intracranial pressure (ICP) monitoring?
Which of the following is a management strategy for intracranial pressure (ICP) monitoring?
Which risk factor is associated with both intracerebral hemorrhage and subarachnoid hemorrhage?
Which risk factor is associated with both intracerebral hemorrhage and subarachnoid hemorrhage?
What is a common characteristic of a transient ischemic attack (TIA)?
What is a common characteristic of a transient ischemic attack (TIA)?
Which of the following is a modifiable risk factor for stroke?
Which of the following is a modifiable risk factor for stroke?
What is the first-line treatment indicated for appropriate patients with acute ischemic stroke?
What is the first-line treatment indicated for appropriate patients with acute ischemic stroke?
Which of the following is recommended for secondary stroke prevention?
Which of the following is recommended for secondary stroke prevention?
What is the main composition of 'white clots' associated with arterial thrombosis?
What is the main composition of 'white clots' associated with arterial thrombosis?
Which of the following parameters is critical to monitor for efficacy in stroke medication management?
Which of the following parameters is critical to monitor for efficacy in stroke medication management?
Which class of medication is primarily used in the management of ischemic stroke?
Which class of medication is primarily used in the management of ischemic stroke?
What is a contraindication for the use of tPA in ischemic stroke treatment?
What is a contraindication for the use of tPA in ischemic stroke treatment?
What is the recommended daily dose of John's wort for a patient with a creatinine clearance (CrCl) greater than 50 mL/min?
What is the recommended daily dose of John's wort for a patient with a creatinine clearance (CrCl) greater than 50 mL/min?
Which monitoring parameters are affected by the use of Factor Xa inhibitors?
Which monitoring parameters are affected by the use of Factor Xa inhibitors?
What is the appropriate action for a patient with a CrCl less than 15 mL/min when considering John's wort?
What is the appropriate action for a patient with a CrCl less than 15 mL/min when considering John's wort?
How should the dose of a Factor Xa inhibitor be adjusted for a patient who is ≥80 years old?
How should the dose of a Factor Xa inhibitor be adjusted for a patient who is ≥80 years old?
What is the mechanism of action for Andexanet alfa?
What is the mechanism of action for Andexanet alfa?
What should be avoided if a patient is already on a lower dose of Factor Xa inhibitors due to drug interactions?
What should be avoided if a patient is already on a lower dose of Factor Xa inhibitors due to drug interactions?
What symptoms may indicate a stroke based on the area of the brain affected?
What symptoms may indicate a stroke based on the area of the brain affected?
Which of the following statements about monitoring with Factor Xa inhibitors is true?
Which of the following statements about monitoring with Factor Xa inhibitors is true?
What is a key recommendation for managing diabetes?
What is a key recommendation for managing diabetes?
Which dietary change is advised for patients with cardiovascular risks?
Which dietary change is advised for patients with cardiovascular risks?
What effect does the combination of clopidogrel and aspirin have?
What effect does the combination of clopidogrel and aspirin have?
Which is a common side effect of ASA + extended-release dipyridamole?
Which is a common side effect of ASA + extended-release dipyridamole?
What is recommended for patients who smoke?
What is recommended for patients who smoke?
Which is true regarding aspirin dosage?
Which is true regarding aspirin dosage?
In which situation might ticagrelor + aspirin be considered?
In which situation might ticagrelor + aspirin be considered?
When considering antiplatelet therapy options, what factors should be taken into account?
When considering antiplatelet therapy options, what factors should be taken into account?
What is the role of clopidogrel in antiplatelet therapy?
What is the role of clopidogrel in antiplatelet therapy?
What defines the main approach for stroke prevention in non-cardioembolic cases?
What defines the main approach for stroke prevention in non-cardioembolic cases?
Flashcards are hidden until you start studying
Study Notes
Stroke Sub-Types
- Ischemic Stroke: Results from arterial occlusion causing reduced blood flow, leads to CNS tissue damage.
- Transient Ischemic Attack (TIA): Temporary neurological dysfunction without infarct; serves as a warning sign for future strokes.
- Hemorrhagic Stroke: Involves bleeding into the brain or CNS, resulting in vascular leakage.
Stroke Statistics
- Fifth leading cause of death in the US with approximately 795,000 strokes annually.
- 15% of strokes occur in individuals with prior TIA.
- Over 7.2 million Americans have reported a history of stroke; it is the leading cause of disability in adults.
Risk Factors for Stroke
- Non-Modifiable Risks: Age, sex (males more than females), race (African American > Hispanic > Caucasian), genetic factors, and family history.
- Modifiable Risks: Hypertension, smoking, diabetes, dyslipidemia, cardiovascular diseases (AFib, CAD, HF, PAD), and lifestyle choices.
- Associated factors: Hormonal contraceptives (estrogen), migraines with aura, substance abuse, hypercoagulable states, high homocysteine levels, and inflammation.
Stroke Classification and Management
- In ischemic strokes, timing is critical as brain tissue needs immediate reperfusion (Time = Tissue).
- Penumbra: Ischemic but salvageable brain tissue surrounding the infarct area.
Reperfusion Therapy
- Eligibility for tPA (tissue Plasminogen Activator) is determined based on clinical guidelines to restore blood flow in cases of ischemic stroke.
Anticoagulants and Antiplatelets
- Oral anticoagulants are tailored based on individual indications including risk assessment and contraindications.
- Anticoagulation management includes factors such as renal function (CrCl) and potential drug interactions impacting dose and safety.
Primary and Secondary Stroke Prevention
- Strategies include lifestyle modifications like diet, exercise, smoking cessation, and annual healthcare assessments.
- Dual antiplatelet therapy may be considered for specific high-risk patients post-minor stroke or TIA events.
Acute Management and Monitoring
- Treatment regimens differ based on stroke subtype; continuous monitoring of efficacy and safety parameters are critical.
- Common medications include aspirin, clopidogrel, and newer anticoagulants with specific dosing adjustments based on kidney function.
Complications from Hemorrhagic Stroke
- Risk factors include hypertension and trauma, with typical presentations involving sudden neurological deficits or severe headaches.
- Management may involve correction of anticoagulant effects, hypertension control, and potential surgical intervention.
Clinical Presentation and Symptoms
- Symptoms vary based on the affected brain region but may include hemiparesis, speech deficits, vertigo, and severe headaches.
Guidelines and References
- Utilization of the 2019 updates and current guidelines for the early management of ischemic stroke, primary prevention, and hemorrhagic stroke management.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
